Distinct Mutation Profiles Between Primary Bladder Cancer and Circulating Tumor Cells Warrant the Use of Circulating Tumors Cells as Cellular Resource for Mutation Follow-up
While circulating tumor cells may serve as minimally invasive cancer markers for bladder cancers, the relationship between primary bladder cancers and circulating tumor cells in terms of somatic mutations is largely unknown. Genome sequencing of bladder tumor and circulating tumor cells is highlighted to identify the somatic mutations of primary bladder cancer.
Bladder cancer tissue was collected by transurethral resection of the bladder and preserved by snap-freezing. Circulating tumor cells were Isolated from the blood obtained before treatment. We performed whole exome sequencing of 20 matched pairs of primary bladder cancers and circulating tumor cells to identify and compare somatic mutations of these two different genomic resources.
We observed that mutation abundances of primary bladder cancers and circulating tumor cells were highly variable. The mutation abundance was not significantly correlated between matched pairs. Of note, the mutation concordance between two resources was only 3–24% across 20 pairs examined, suggesting that the circulating tumor cell genomes of bladder cancer patients might be genetically distinct from primary bladder cancers. A relative enrichment of mutations belonging to APOBEC-related signature and a depletion of C-to-G transversions were observed for primary- and circulating tumor cells specific mutations, respectively, suggesting that distinct mutation forces might have been operative in respective lesions during carcinogenesis.
The observed discrepancy of mutation abundance and low concordance level of mutations between genomes of primary bladder cancers and circulating tumor cells should be taken into account when evaluating clinical utility of circulating tumor cells for treatments and follow-up of bladder cancers.
Patients were selected and registered retrospectively, and medical records were evaluated.
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
On 18 Nov, 2020
On 03 Nov, 2020
On 03 Nov, 2020
On 30 Oct, 2020
Posted 10 Jul, 2020
On 26 Oct, 2020
Received 22 Oct, 2020
On 19 Oct, 2020
Received 15 Oct, 2020
On 23 Sep, 2020
Invitations sent on 21 Aug, 2020
On 09 Jul, 2020
On 09 Jul, 2020
On 09 Jul, 2020
Distinct Mutation Profiles Between Primary Bladder Cancer and Circulating Tumor Cells Warrant the Use of Circulating Tumors Cells as Cellular Resource for Mutation Follow-up
On 18 Nov, 2020
On 03 Nov, 2020
On 03 Nov, 2020
On 30 Oct, 2020
Posted 10 Jul, 2020
On 26 Oct, 2020
Received 22 Oct, 2020
On 19 Oct, 2020
Received 15 Oct, 2020
On 23 Sep, 2020
Invitations sent on 21 Aug, 2020
On 09 Jul, 2020
On 09 Jul, 2020
On 09 Jul, 2020
While circulating tumor cells may serve as minimally invasive cancer markers for bladder cancers, the relationship between primary bladder cancers and circulating tumor cells in terms of somatic mutations is largely unknown. Genome sequencing of bladder tumor and circulating tumor cells is highlighted to identify the somatic mutations of primary bladder cancer.
Bladder cancer tissue was collected by transurethral resection of the bladder and preserved by snap-freezing. Circulating tumor cells were Isolated from the blood obtained before treatment. We performed whole exome sequencing of 20 matched pairs of primary bladder cancers and circulating tumor cells to identify and compare somatic mutations of these two different genomic resources.
We observed that mutation abundances of primary bladder cancers and circulating tumor cells were highly variable. The mutation abundance was not significantly correlated between matched pairs. Of note, the mutation concordance between two resources was only 3–24% across 20 pairs examined, suggesting that the circulating tumor cell genomes of bladder cancer patients might be genetically distinct from primary bladder cancers. A relative enrichment of mutations belonging to APOBEC-related signature and a depletion of C-to-G transversions were observed for primary- and circulating tumor cells specific mutations, respectively, suggesting that distinct mutation forces might have been operative in respective lesions during carcinogenesis.
The observed discrepancy of mutation abundance and low concordance level of mutations between genomes of primary bladder cancers and circulating tumor cells should be taken into account when evaluating clinical utility of circulating tumor cells for treatments and follow-up of bladder cancers.
Patients were selected and registered retrospectively, and medical records were evaluated.
Figure 1
Figure 2
Figure 3